DEVELOPMENT OF CARBON TETRACHLORIDE-INDUCED CHRONIC HEPATOTOXICITY MODEL IN RATS AND ITS APPLICATION IN EVALUATION OF HEPATOPROTECTIVE ACTIVITY OF SILYMARIN by Shah, Gopi H et al.
Vol 10, Issue 8, 2017
Online - 2455-3891 
Print - 0974-2441
DEVELOPMENT OF CARBON TETRACHLORIDE-INDUCED CHRONIC HEPATOTOXICITY MODEL 
IN RATS AND ITS APPLICATION IN EVALUATION OF HEPATOPROTECTIVE ACTIVITY OF 
SILYMARIN
GOPI H SHAH1, BHARAT G PATEL2, GAURANG B SHAH3
1Department of Pharmacology and Toxicology, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, 
CHARUSAT – Campus, Changa, Petlad, Anand - 388 421, Gujarat, India. 2Department of Pharmacology, Charotar University of Science 
and Technology, CHARUSAT – Campus, Changa, Petlad, Anand - 388 421, Gujarat, India. 3Department of Pharmacology and Toxicology, 
K.B.Institute of Pharmaceutical Education and Research, Sector-23, GH-6, Gandhinagar, Gujarat, India. Email: ghshah17213@gmail.com
Received: 25 March 2017, Revised and Accepted: 11 May 2015
ABSTRACT
Objective: The objective of the present work is to develop carbon tetrachloride (CCl4)-induced chronic hepatotoxicity model in rats and its application 
in evaluation of hepatoprotective activity of silymarin.
Methods: Animals were divided into four groups. Three groups were the disease induction group and 4th was the treatment group. In disease induction 
groups, chronic liver injury was induced by administration of CCl4 through intraperitoneal route (1 ml/kg) for 7-8 weeks. For treatment Group, 1 ml 
silymarin suspension (orally) and CCl4 was given for 7-8 weeks. During disease induction and treatment period (7-8 weeks), blood samples were 
collected and serum was separated which in turn used to analyze liver function tests such as serum glutamate oxaloacetate transaminase (SGOT), 
serum glutamate pyruvate transaminase (SGPT), alkaline phosphate (ALP), direct bilirubin, total protein (TP), and albumin (Alb) levels. Along with 
liver functional tests, tests to check cholesterol, glucose, and malondialdehyde (MDA) were also performed. Liver fibrosis and cirrhosis was quantified 
by histopathological studies of small portion of the excised liver. Model was validated by repetition of the experiment. Intermediate dissection was 
carried out to measure an extent of liver damage.
Result: Serum SGOT, SGPT, ALP, and direct bilirubin were found to be significantly higher in CCl4 intoxicated rats. TP and Alb were decreased, and 
MDA was found to be significantly higher in CCl4 intoxicated rats, which is the main end product of lipid peroxidation. Whereas in the treatment group 
silymarin improved the liver functions in CCl4 toxicated drug.
Conclusion: We conclude that protein oxidation may play a role in the pathogenesis of CCl4 induced liver injury. The accumulation of oxidized proteins 
may be an early indication of CCl4 induced liver damage and silymarin found to be effective in liver injury by inhibiting protein oxidation.
Keywords: Liver fibrosis, Free radicals, Lipid peroxidation, Oxidative stress, Carbon tetrachloride, Liver biomarkers.
INTRODUCTION
The liver is the largest organ within the body, involved in metabolism of 
drugs. Among total liver mass, hepatocytes are involved in detoxification 
of a variety of drugs, vitamins, hormones, and environmental toxicants 
and the metabolism of amino acids and ammonia, biochemical oxidation 
reactions. Kupffer cells are a reservoir of fixed macrophages, which 
play a protective role against gut-derived toxins that have escaped 
into the portal circulation. Endotoxins are mainly responsible for the 
production of cytokines. Other specific liver cell types also perform the 
unique function. The liver is the main organ in the first line of defense; 
it appears to be the most common target organ damaged by industrial 
chemicals [1]. Occupational and environmental liver diseases may 
present with a wide clinical spectrum ranging from asymptomatic 
liver enzyme elevation to acute liver failure, cirrhosis, and cancer. 
Hepatocellular necrosis may occur due to most industrial chemicals, 
including solvents, exhibit dose-dependent hepatocyte cytotoxicity [2].
Liver injury of various etiologies can cause liver fibrosis, which further 
progresses to end stage liver failure (cirrhosis and ascites) which 
was characterized by progressive accumulation of connective tissue 
in the liver [3]. Recruitment of immune cells of the liver leads to the 
activation of local Kupffer cells, which can further promote the fibrotic 
process through secretion of inflammatory and fibrogenic cytokines. 
The causes of liver injuries are toxic chemicals such as antibiotics, 
chemotherapeutic agent’s aflatoxins, chlorinated hydrocarbons, and 
carbon tetrachloride (CCl4).
Due to multiplicity and complexity of liver function as no single 
test is enough to define the extent of liver damage and to evaluate 
hepatoprotective activity of the drugs. As every toxicant has unique 
mode of action, so selection of toxicant depends on type and 
nature of liver injury required, which produce the specific type of 
damage [4]. CCl4 proves highly useful as an experimental model for 
the study of certain hepatotoxic effects [5]. It consistently produces 
liver injury in many species. The formations of free radicals are 
responsible in pathogenesis of CCl4-induced liver injury in rats and 
alcohol-induced liver injury in humans. Free radicals are the main 
culprit for lipid peroxidation which leads to oxidative damage to 
cellular proteins and alters its functions. The main principle effect 
of CCl4-induced liver injury is the lipid peroxidative degradation of 
biomembrane [6]. In liver biotransformation of CCl4 produce its active 
metabolite trichloromethyl free radical (CCl3*) [7], which binds to the 
macromolecule and induces peroxidative degradation of membrane 
lipids leads to the formation of toxic aldehyde, which is responsible 
for the liver injury.
In the absence of consistent liver-protective drugs in modern medicine, 
a large number of plant-derived natural products such as flavonoids, 
terpenoids, and steroids have received considerable attention during 
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recent years due to their diverse pharmacological properties, including 
antioxidant and hepatoprotective activity [8].
Silybum or milk thistle was the most commonly used herbal treatment 
of liver diseases. Silymarin is the main active constituent. It has been 
reported that silymarin protects liver cells from a wide variety of 
toxins, mainly acetaminophen, ethanol, CCl4, and D-galactosamine [9]. 
Silymarin produced its hepatoprotective effects through several 
mechanisms including antioxidation [10], inhibition of lipid 
peroxidation [11], enhanced liver detoxification via inhibition of Phase 
I detoxification and enhanced glucuronidation [12], and protection of 
glutathione (GSH) depletion [13].
Silymarin elicited a significant hepatoprotective activity by lowering 
the levels of serum marker enzymes and lipid peroxidation and elevated 
the levels of GSH, superoxide dismutase, catalase, albumin (Alb) and 
total protein (TP) in a dose dependant manner, which was confirmed 
by the decrease in the total weight of the liver and histopathological 
examination [14]. Silymarin increases hepatocyte protein synthesis 
and thus promoting hepatic tissue regeneration [15]. From the 
animal study, it was proven that silybin reduces the conversion of 
hepatic stellate cells into myofibroblasts, slowing or even reversing 
fibrosis [16].
The aim of the proposed work is to develop hepatotoxicity model 
(chronic) in rats and define chronicity of the disease by measuring 




CCl4 and Arachis oil were purchased from Loba Chemie Pvt Ltd., 
Mumbai. Silymarin suspension was from Microlabs Ltd., Bengaluru, 
Karnataka. Serum glutamate pyruvate transaminase (SGPT), serum 
glutamate oxaloacetate transamina (SGOT), bilirubin, TP, Alb, glucose, 
cholesterol, and Kits were purchased from Autospan (Span Diagnostic 
Pvt., Limited Surat).
EXPERIMENTAL PROTOCOL AND PROCEDURE
Animals
The experiment was performed after approval from the Institutional 
Animal Ethics Committee (IAEC). The approved protocol number 
is RPCP/IAEC/2013-2014/R-32. Healthy Wistar rats of either sex, 
weighing 200-250 g was taken during the experiment. The animals 
were housed in the polypropylene cage at 25°C; 12 hrs dark-light cycle, 
with free access to standard pellet diet (normal pellet diet) and water 
ad libitum during the experiment. The animals were acclimatized to 
surround for 1 week before experiment.
Experimental design
In rats, chronic liver injury was induced by exposure of hepatotoxicant 
such as CCl4. The mixture of CCl4 and Arachis oil (1:1) with the dose of 
1 ml/kg was given intraperitoneally (i.p.) [17].
Rats were randomly divided as follows:
•	 Group	 Ia	 and	 Ib:	 Received	 normal	 saline	 1	ml/kg	 per	 day	 for	
7-8 weeks.
•	 Group	IIa:	Received	CCl4 1 ml/kg 1st for 10 days daily and then after 
1 ml/kg twice a week up to 7-8 weeks.
•	 Group	IIb:	Received	CCl4 1 ml/kg 1st for 10 days alternate and then 
after 1 ml/kg twice a week up to 7-8 weeks.
•	 Group	IIIa:	Received	CCl4 1 ml/kg 1st for 10 days daily and then after 
1 ml/kg twice a week up to 7-8 weeks.
•	 Group	IIIb:	Received	CCl4 1 ml/kg 1st for 10 days alternate and then 
after 1 ml/kg twice a week up to 7-8 weeks.
•	 Group	IV:	Received	CCl4 1 ml/kg (i.p) and 1 ml silymarin suspension 
(p.o) for 7-8 weeks days.
Blood sample collection
Blood samples were collected by retro-orbital route in ethylene diamine 
tetra acetate (EDTA) containing and EDTA-free vials on day 0, 7, 14, 
21, 28, 35 and 49 during development and treatment of the model. 
After collection of blood samples, the samples were centrifuged under 
cooling condition at 4000 RPM for 10-15 minutes to separate plasma 
and serum. Plasma was used to measure all biochemical parameters 
such as aspartate aminotransferase (AST), alanine transaminase (ALT), 
bilirubin, Alb, TP, glucose, cholesterol and malondialdehyde (MDA), 
whereas serum was used to measure alkaline phosphate (ALP) activity.
Histopathological investigation
Rats were kept on fasting. Rats of Groups IIa and IIb were sacrificed on 
day 35, whereas rats of Groups IIIa and IIIb were sacrificed on day 49.
The liver was collected and washed with ice-cold saline. The excised liver 
was fixed in 10 % formalin solution and taken to the Anand Agricultural 
University, Department of Histopathology, for histopathological study. 
The extent of CCl4 induced liver injury was evaluated by assessing the 
morphological changes in liver sections stained with Haematoxylin and 
Eosin Stain and Masson trichomes stain to observe liver fibrosis.
Statistical analysis
All parameters were expressed as a mean value±standard deviation. 
Differences between the mean value of tests and controls were 
evaluated statistically by Student’s t-test. p<0.05 was regarded as 
statistically significant.
RESULTS AND DISCUSSION
CCl4 was given daily (for 35 days); there was the rise in ALP, AST, MDA, 
glucose, cholesterol, and globulin. The similar effect was also seen when 
it was given alternatively (For 35 days). However, different scenarios 
were seen in normal controls (Table 1). Same way, when CCl4 was 
given daily (for 49 days), there was rise in ALP, AST, MDA, glucose, 
cholesterol, and globulin. The similar effect was also seen when it was 
given alternatively (for 49 days) (Table 2). When silymarin was given 
to CCl4 treated group, all liver parameters such as ALP, AST, and ALT are 
normalized. It also normalizes TP, Alb, MDA, glucose, cholesterol, and 
globulin similarly as in normal controls (Table 3).
Histopathological findings
The controlled rats show normal liver architecture. They show normal 
hepatocytes, portal triads vasculature, and bile duct. Whereas rats 
which were given CCl4 up to 35 days and 49 days show extensive liver 
damage (Figs. 1 and 2), respectively. Silymarin treated rats show normal 
liver architecture.
DISCUSSION
The liver is largest organ and is target for toxicity because of its role 
in clearing and metabolizing chemicals through the process called 
detoxification [18]. The most commonly used approach to induce toxin-
mediated experimental liver fibrosis is the periodic administration of 
CCl4 in mice or rats [19]. It was used extensively in animal models of 
acute hepatic failure in the seventies and early eighties. More recently, it 
has been used in the development of cirrhosis animal models following 
its gastric and intraperitoneal administration [20]. The most studies rely 
on the CCl4-model to induce toxic liver fibrosis in mice due to the good 
comparability, excellent reproducibility, and moderate burden for the 
animals [19]. Histopathological sectioning of the liver tissues indicated 
that CCl4 can induce fibrosis, cirrhosis, and hepatocarcinoma [21]. 
The toxic effect of CCl4 was due to trichloromethyl radical produced 
during oxidative stress [22]. The liver injury induced by CCl4 increases 
the number of infiltrated neutrophils, macrophages, Kupffer cells, 
lymphocytes and natural killer cells which further induced activation 
of liver resident macrophages and/or chemo attraction of extra 
hepatic cells (e.g., neutrophils and lymphocytes) [23]. Liver fibrosis, 
inflammation, and injury were induced by release of activated 
macrophages [24].
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Table 1: Change in various serum parameters in rats exposed to CCl4 daily and CCl4 alternate (for 35 days)
Group ALP ALT AST Bilirubin TP
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Data were expressed as mean±SEM (n=6). Significant difference was indicated by p<0.5 compared with normal control group. p value between normal control 
and CCl4 treated group is<0.5, which indicates they are statistically significant. Whereas p value between CCl4 daily and CCl4 alternate group is not <0.5, which 
indicates no significant difference in between this group. ALP: Alkaline phosphate, ALT: Alanine transaminase, AST: Aspartate transaminase, TP: Total protein, 
MDA: Malondialdehyde, CCl4: Carbon tetrachloride, SEM: Standard error of the mean
Table 2: Change in various serum parameters in rats exposed to CCl4 daily and CCl4 alternate (for 49 days)
Group ALP ALT AST Bilirubin T.P
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Data were expressed as mean±SEM (n=6). Significant difference was indicated by p<0.5 compared with normal control group. Here, p value between normal control 
and CCl4 treated group is<0.5, which indicates they are statistically significant. Whereas p value between CCl4 daily and CCl4 alternate group is not<0.5, which 
indicates no significant difference in between this group. ALP: Alkaline phosphate, ALT: Alanine transaminase, AST: Aspartate transaminase, TP: Total protein, 
MDA: Malondialdehyde, CCl4: Carbon tetrachloride, SEM: Standard error of the mean
Table 3: Effect of CCl4 and CCl4+silymarin on various biochemical parameters on wistar rats










































Data were expressed as mean±SEM (n=6). Significant difference was indicated by p<0.5 compared with normal control group. Here p value between normal control and 
CCl4 treated group, CCl4 treated group and silymarin treated group is <0.5, so they were statistically significant. ALP: Alkaline phosphate, ALT: Alanine transaminase, 
AST: Aspartate transaminase, TP: Total protein, MDA: Malondialdehyde, CCl4: Carbon tetrachloride, SEM: Standard error of the mean
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For acute liver injury rats were administered a single dose of CCl4, 
2 ml/kg of body weight which leads to liver fibrosis. The chronic dose 
of CCl4 was 2 ml/kg of body weight twice per week which result in liver 
fibrosis [25]. In this study, the development of chronic model rats was 
administered 1.0 ml/kg of body weight of CCl4 i.p. for 10 days daily and 
then after 1 ml/kg twice a week up to 7-8 weeks.
Serum aminotransferase enzymes
Upon cellular membrane damage and leakage serum activities were 
increased [26]. In all types of liver injury, serum aminotransferase 
activities were increased. Serum estimation of SGPT was specific 
for the liver tissue so in liver cell injury serum SGPT was of greater 
value, whereas SGOT level may increase in acute necrosis or 
ischemia of other organs such as the myocardium, besides the liver 
cell injury.
In this study, serum AST, ALT, ALP, and bilirubin activities were greatly 
increased (p<0.05) in rats exposed to CCl4 as compare to normal 
control. The increased serum levels of hepatic markers have been 
attributed to the liver injury because these enzymes are placed in the 
cytoplasmic area of the cell and are released into circulation in case of 
cellular damage [27].
Zimmerman et al. stated that serum level of ALP, AST, ALT, and 
bilirubin was increased by mitochondrial damage in liver cells this 
damage was induced by CCl4 [28]. The activities of liver enzymes were 
significantly elevated after CCl4 treatment this was reported by many 
authors [29,30].
Binita et al. reported that chronic liver fibrosis was induced in Wistar 
rats by oral administration of CCl4 for 7 weeks [31], whereas in the 
present study liver fibrosis was induced within 5 weeks. The proposed 
animal model in this study fulfilled the criteria described by Terblanche 
and Hickman [32].
It has been reported that silymarin stabilizes the membrane of 
hepatocytes, preventing toxins from entering the cell through 
enterohepatic recirculation, regenerates liver by stimulating nucleolar 
polymerase A and increasing ribosomal protein synthesis [33]. Silymarin 
comprises a strong antioxidant and anti-inflammatory potential [33]. 
Silymarin inhibits hepatic lipid peroxidation, thus it protects against 
membrane damage. Toxicity effect of CCl4 was controlled by restoration 
of serum bilirubin, proteins and enzymes [34].
In the present study, silymarin improves liver function. It decreases 
liver SGPT, SGOT, ALP, Bilirubin, MDA, and globulin level. Silymarin 
also controls TP and Alb level. Silymarin helps in regenerating 
liver tissue, controls inflammation, enhances glucuronidation, 
and protects against GSH depletion. The non-traditional use of 
silymarin protects other organs along with the liver. Silymarin also 
prevents the absorption of toxins into hepatocytes by occupying to 
the binding site and also inhibits the transport of protein into the 
membranes [35].
Histopathological investigations
The histopathological evaluation of CCl4-induced toxicity in all groups 
at the different time intervals was examined. The normal control 
group (Fig. 3) shows no abnormalities, whereas in CCl4 treated group 
(both day 35 and day 49) shows liver abnormalities. On day 35, liver 
fibrosis (Fig. 1) was seen and on day 49, liver cirrhosis was seen (Fig. 2). 
Silymarin treated animals show normal liver architecture (Fig. 4).
CONCLUSION
From the results, it was concluded that CCl4 has potential to cause 
chronic liver injury (fibrosis and cirrhosis). The proposed animal 
model of chronic liver injury might be suitable for screening of drugs 
used to treat liver injury and associated disorders. Here, silymarin 
as a standard drug shows hepatoprotective effect in the developed 
model.
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Fig. 3: Normal histology of liver
Fig. 1: Masson’s trichome stain reveled proliferation of fibrous 
connective tissue in hepatic (on day 35) (carbon tetrachloride 
1 ml/kg)
Fig. 2: Proliferation fibrous were evident in hepatic lobule 
resulting into pseudolobulation (on day 49) (carbon tetrachloride 
1 ml/kg)
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